Progress on ABN AMRO share buyback programme 15 April – 21 April 2022
Progress on ABN AMRO share buyback programme 15April – 21April2022
ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 9 February 2022.
During the week of 15 April 2022 up to and including 21 April 2022 a total of 2,048,579 shares and depositary receipts were repurchased at an average price of €12.30 for a total amount of €25,194,557.62.
For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme
To date the total consideration for shares and depositary receipts repurchased amounts to € 394,231,178 representing 78.85% of the overall share buyback programme.
This press release is published by ABN AMRO Bank N.V. and contains information that is to be made publicly available under Regulation (EU) No 596/2014 (Market Abuse Regulation)
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
RESULT OF RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS24.5.2022 11:30:00 CEST | Press release
AuctionAuction resultsAuction date2022-05-24Maturity2025Tendered volume, SEK mln500 +/- 500Offered volume, SEK mln994Volume bought, SEK mln0Number of bids4Number of accepted bids0 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln34450000Volume bought, SEK mln0000Number of bids2100Number of accepted bids0000Average yield, %----Lowest accepted yield, %----Highest yield, %----Accepted at lowest yield, %---- QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln150000Volume bought, SEK mln0000Number of bids1000Number of accepted bids0000Average yield, %----Lowest accepted yield, %----Highest yield, %----Accepted at lowest yield, %----
Nexstim Receives an Order for Two NBS Systems from a Finnish University Hospital24.5.2022 11:30:00 CEST | Press release
Press release, Helsinki, 24 May 2022 at 12:30 PM (EEST) Nexstim Receives an Order for Two NBS Systems from a Finnish University Hospital Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received an order for two NBS 5 systems from a university hospital in Finland. The customer is an experienced user of the Nexstim NBS 4 system, now acquiring the two new systems to replace the old system and to increase capacity. Nexstim’s NBS (Navigated Brain Stimulation) system is used, for example, in planning neurosurgery or radiation therapy after a patient has had a diagnosis of a brain tumor or other disorder. When the lesion is predicted to be close to functional areas of the brain—such as those responsible for speech production and limb movement —the brain maps generated with NBS can be invaluable when deciding the best, personalized treatment option for the patient. These specific NBS systems also include the software of an NBT® (Navigated Brain Therapy) system, allowing the sys
Sweegen Wins Stevia Reb M Patent Lawsuit Against PureCircle24.5.2022 11:04:00 CEST | Press release
Rancho Santa Margarita, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Sweegen, the global pioneer in wellness ingredient technologies and innovations, announced its victory against PureCircle in a stevia Rebaudioside M (Reb M) patent lawsuit. "Today's judgment vindicates Sweegen and affirms the company's position as an industry leader in innovative sweetener solutions," said Steven Chen, CEO of Sweegen. PureCircle, acquired by Ingredion in 2020, had filed the 2018 lawsuit against Sweegen in the U.S. District Court for the Central District of California, accusing Sweegen of infringing two PureCircle patents covering the manufacture of Reb M. The legal tide turned on PureCircle when Sweegen obtained a summary judgment that both of PureCircle's asserted patents are invalid. Since it is impossible to infringe an invalid patent, the court's invalidation of the asserted patents ends the infringement case against Sweegen at the U.S. District Court. "As a holder of core proprietary technologies of
Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities24.5.2022 11:00:00 CEST | Press release
Company Announcement No. 38/2022 Copenhagen, 24 May 2022 Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Anders Obel 2. Reason for the notification a) Position/title Member of the Board of Directors b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Sale of shares c) Price(s) and volume(s) Price(s)Volume(s)DKK 147.6 7,
Disclosure of voting rights for Chairman of the Board24.5.2022 10:44:47 CEST | Press release
Oslo, 24 May 2022. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 25 May 2022. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 7,234,249 additional shares. In total, Mr. Bøhn will represent and vote for 19.7 per cent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 25 May 2022. This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CFO, firstname.lastname@example.org, Mobile: +47 9400 5757